We’re amidst a revolution in how cancer is treated and cured.
Our scientists and researchers work tirelessly each day to get in front of cancer. They apply their patient-centric ideology and deep understanding of disease biology to transform outcomes in solid tumors. These efforts are leading the way to replace highly invasive treatments, such as surgery and chemotherapy, with multi-targeted combination regimens that engage a person’s own immune system to fight cancer and improve overall survival.
Johnson & Johnson has been redefining the cancer treatment paradigm for more than three decades, and since 2011 brought to market 14 new oncology medicines that have advanced the standard of cancer care. Our presence at this year’s World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) Congress continues that legacy, with twenty-seven studies (23 company-sponsored and four investigator-initiated), including four late-breaking abstracts, featuring our latest data in lung, prostate, and bladder, as well as never-before-shared findings in colorectal cancer.
“This latest data reflect our ambition to redefine the standard of cancer care for patients and our insatiable drive to eliminate the disease,” said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology. “As the world’s largest healthcare company, we are leading where medicine is going, pioneering therapeutic advances that change and save lives.”
“Our approach to treating cancer means delivering treatments that patients need, while also ensuring they can access them,” said Andreas Gerber, Worldwide Vice President Oncology Global Commercial Strategy Organization, Johnson & Johnson Innovative Medicine. “We strive to be an ally to the scientific, regulatory, and patient communities, championing policies that enable access, affordability, and a sustainable innovation system, so that we can continue to invest in and pursue tomorrow’s cures.”
